A Breakthrough at SickKids Hospital
Doctors and researchers at The Hospital for Sick Children (SickKids) in Canada have achieved a significant medical milestone by halting the progression of a rare genetic disorder in a young boy named Michael through innovative gene therapy.
Michael’s Battle with SPG50
Michael, diagnosed with spastic paraplegia type 50 (SPG50), received individualized gene therapy in March 2022. SPG50 is an “ultra-rare” progressive neurodegenerative disorder that causes developmental delays, speech impairment, seizures, and paralysis of all four limbs, typically proving fatal by adulthood. Only about 80 children worldwide are affected by this condition.
Groundbreaking gene therapy treatment
To slow the disease’s progression, a clinical research team at SickKids administered a unique single-patient gene therapy to Michael, less than three years after his initial diagnosis. Gene therapy involves delivering a healthy copy of a gene into the cells of a person with faulty genes. In Michael’s case, SPG50 is caused by two pathogenic variants in the AP4M1 gene.
Encouraging results and future implications
Dr. Jim Dowling, Staff Physician in the Division of Neurology and Senior Scientist in the Genetics & Genome Biology program at SickKids, highlighted the broader implications: “While these ultra-rare diseases are unique, our workflow provides a roadmap for gene therapies that could help many of the thousands of children in Canada with rare genetic conditions.”
Following the therapy, Michael showed significant improvements, including the ability to stand with his heels on the ground and enhancements in neurodevelopmental aspects.
Michael’s parents, Terry and Georgia, shared their emotional journey: “When we heard that Michael had been diagnosed with this terrible disease, our world fell apart. Thankfully, we had an amazing team at SickKids and a supportive community that lifted us up and gave us the confidence to raise millions of dollars and create a therapy, not only for Michael, but for other children affected by this disease for generations to come.”
This remarkable success story, published in the Nature journal, underscores the potential of gene therapy to transform the lives of children with rare genetic disorders.
